OpenAlex
PricingAboutJobs
Log inGet started
Work

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

HTML

Year: 2013
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-12-1182
Authors: Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umana, Gerhard Niederfellner, Marina Bacac, Christian Klein
Institutions: F. Hoffmann-La Roche AG, Centre National de la Recherche Scientifique, Inserm, Centre de Recherche en Cancérologie de Lyon, Lyon 1 Université
Language: English

Topic: Lymphoma Diagnosis and Treatment
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: obinutuzumab, rituximab, ofatumumab, anti-CD20 monoclonal antibody, glycoengineering, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, B-cell depletion, antibody internalization, rituximab resistance, non-Hodgkin lymphoma
SDG: Good health and well-being

Open Access status: closed

Funders: Roche Innovation Center Zurich, University of Leicester
OpenAlex ID: W2135802989
FWCI: 23.98
Cites: 38
Cited by: 407
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security